233 related articles for article (PubMed ID: 35447344)
1. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Meiring L; Petzer JP; Legoabe LJ; Petzer A
Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Youdim MB; Gross A; Finberg JP
Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
7. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
[TBL] [Abstract][Full Text] [Related]
8. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Tabakman R; Lecht S; Lazarovici P
Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
14. Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study.
Tandarić T; Prah A; Stare J; Mavri J; Vianello R
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32858935
[TBL] [Abstract][Full Text] [Related]
15. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
16. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2012 Apr; 119(4):405-14. PubMed ID: 22065207
[TBL] [Abstract][Full Text] [Related]
17. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
Freedman NM; Mishani E; Krausz Y; Weininger J; Lester H; Blaugrund E; Ehrlich D; Chisin R
J Nucl Med; 2005 Oct; 46(10):1618-24. PubMed ID: 16204711
[TBL] [Abstract][Full Text] [Related]
18. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Youdim MB; Tipton KF
Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419
[TBL] [Abstract][Full Text] [Related]
19. Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline.
Tandarić T; Vianello R
ACS Chem Neurosci; 2019 Aug; 10(8):3532-3542. PubMed ID: 31264403
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanism and Structure-activity Relationship of the Inhibition Effect between Monoamine Oxidase and Selegiline Analogues.
Yang C; Wang X; Gao C; Liu Y; Ma Z; Zang J; Wang H; Liu L; Liu Y; Sun H; Wang W
Curr Comput Aided Drug Des; 2024; 20(5):474-485. PubMed ID: 37138424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]